相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors
Adedayo A. Onitilo et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies
Ursula J. E. Seidel et al.
FRONTIERS IN IMMUNOLOGY (2013)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Metastatic Behavior of Breast Cancer Subtypes
Hagen Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules
Gabriela Kramer-Marek et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Effect of the Lipid Chain Melting Transition on the Stability of DSPE-PEG (2000) Micelles
Mark Kastantin et al.
LANGMUIR (2009)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
G. Valabrega et al.
ANNALS OF ONCOLOGY (2007)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
SK Mohsin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging
R Saito et al.
CANCER RESEARCH (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Engaged and bystander T cell receptors are down-modulated by different endocytotic pathways
A Monjas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Clinical trials of Herceptin (R) (trastuzumab)
J Baselga
EUROPEAN JOURNAL OF CANCER (2001)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma
MJ Smyth et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
